Undisclosed ADC therapeutic / Solve Therap, Nerviano Medical Sciences - LARVOL DELTA

Targeting a novel surface antigen, ryk, with the antibody-drug conjugate, slv-404, is effective in richter transformation patient-derived xenografts (ASH 2025) - "In summary, these results show that the novel antigen RYK is a suitable target for an ADC therapy. Moreover, we demonstrated the therapeutic potential of a novel RYK-based ADC for the treatment of RT, still representing a significant unmet clinical need."

Clinical • B Cell Lymphoma • Burkitt Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Richter's Syndrome • IL15 • ROR1 • TOP1